GlassScriptPhysician profile
Gary A Bergen
NPI 1295833812
$2,515.39
in general payments reported to CMS, 2019-2025
17 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.52 · 2020: $147 · 2021: $17.46 · 2022: $299 · 2023: $859 · 2024: $804 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919 · Education: $34.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.65 |
| Education | $34.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $625.59 | 2019-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $305.16 | 2020-2025 | Nuzyra |
| Gilead Sciences, INC. | $277.03 | 2023-2025 | |
| Abbvie INC. | $241.93 | 2021-2024 | Avycaz, Mavyret |
| Melinta Therapeutics, LLC | $180.29 | 2023-2024 | Orbactiv, Kimyrsa, Rezzayo |
| Angiodynamics, INC. | $173.64 | 2019-2023 | Angiovac |
| Shionogi INC | $158.64 | 2023-2025 | Fetroja |
| Viiv Healthcare Company | $134.41 | 2022-2025 | Dovato |
| Merck Sharp & Dohme LLC | $128.85 | 2023-2024 | Dificid, Recarbrio, Zerbaxa |
| Ferring Pharmaceuticals INC. | $84.31 | 2022-2024 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $57.92 | 2024-2025 | Hyqvia, Cuvitru |
| La Jolla Pharmaceutical Company | $45.29 | 2023 | Xerava |
| Glaxosmithkline, LLC. | $25.79 | 2022 | |
| X4 Pharmaceuticals, INC. | $24.77 | 2024 | Xolremdi |
| Janssen Biotech, INC. | $18.71 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $17.43 | 2023 | Pico |
| Idorsia Pharmaceuticals US INC | $15.63 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bergen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.